Shares of NeuroMetrix, Inc. (NASDAQ:NURO – Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.84 and traded as high as $4.23. NeuroMetrix shares last traded at $3.89, with a volume of 27,374 shares trading hands.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on shares of NeuroMetrix in a research report on Wednesday. They issued a “sell” rating on the stock.
Read Our Latest Research Report on NURO
NeuroMetrix Trading Down 2.4 %
NeuroMetrix (NASDAQ:NURO – Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share (EPS) for the quarter. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%. The company had revenue of $0.77 million during the quarter.
NeuroMetrix Company Profile
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.
See Also
- Five stocks we like better than NeuroMetrix
- 5 Top Rated Dividend Stocks to Consider
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- What Are Some of the Best Large-Cap Stocks to Buy?
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- What are earnings reports?
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.